E
VIR icon

Ergoteles’s Vir Biotechnology VIR Stock Holding History

Ergoteles’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,031
Closed -$257K – 1553
2023
Q1 		$257K Buy
+11,031
New +$282K 0.01% 937
2022
Q3 		– Sell
-112,000
Closed -$2.85M – 2012
2022
Q2 		$2.85M Sell
112,000
-71,447
-39% -$1.67M 0.09% 237
2022
Q1 		$4.72M Buy
+183,447
New +$5.44M 0.18% 137

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Ergoteles's VIR Position: Q2 2023 in Review

Ergoteles sold out of Vir Biotechnology (VIR) in Q2 2023, closing a stake of 11,031 shares — an estimated $257K sold.

Ergoteles first reported a position in VIR in Q1 2022 and held it in 3 quarters. The position peaked at $4.72M in Q1 2022. 226 funds tracked by Wall St. Rank hold VIR as of Q2 2023.

  • Ergoteles reported no remaining Vir Biotechnology position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 11,031 Vir Biotechnology shares in Q2 2023, an estimated $257K.
  • Ergoteles first reported a position in Vir Biotechnology in Q1 2022 and held it in 3 quarters.
  • Ergoteles's Vir Biotechnology position peaked at $4.72M in Q1 2022.
  • 226 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.